retatrutide phase 2 results obesity nejm 2023 𧬠R3TA is a next-generation peptide being studied for its unique triple-receptor approach to metabolic health. Unlike traditional GLP-1 therapies, R3TA is designed to interact with three metabolic pathways simultaneously: GLP-1, GIP The trial that put β24%β
Pay in 4 interest-free payments of $5.43 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 1 - Aug 6



























